Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone

Journal of Oral Pathology and Medicine

Volumn 41, Issue 6, 2012, Pages 494-499

  Abtahi, Jahan ^a,b   Agholme, Fredrik ^a   Sandberg, Olof ^a   Aspenberg, Per ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bisphosphonate associated osteonecrosis of the jaw; Bisphosphonates; Osteonecrosis; Rat

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG; VORENVET;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG INDUCED DISEASE; IMMUNOHISTOCHEMISTRY; JAW OSTEONECROSIS; MALE; MOLAR TOOTH; NONHUMAN; OSTEOCYTE; PRIORITY JOURNAL; RAT; TOOTH EXTRACTION;

ALENDRONATE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; CELL DEATH; CELL SURVIVAL; DEXAMETHASONE; DISEASE MODELS, ANIMAL; GINGIVAL DISEASES; GINGIVECTOMY; GLUCOCORTICOIDS; L-LACTATE DEHYDROGENASE; MALE; MAXILLA; MOLAR; ORAL ULCER; OSTEOCYTES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TOOTH EXTRACTION; TOOTH SOCKET; WOUND HEALING;

EID: 84863446443     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2011.01125.x     Document Type: Article

References (32)

1. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-75.
2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-34.
3. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61: 1104-7.
4. Marx RE Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7.
5. Arduino PG, Menegatti E, Scoletta M, et al. Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws. J Oral Pathol Med 2011; 40: 510-5.
6. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002; 8: 1080-4.
7. Aspenberg P. Osteonecrosis of the jaw: what do bisphosphonates do? Expert Opin Drug Saf 2006; 5: 743-5.
8. Aspenberg P. Osteonecrosis: what does it mean? One condition partly caused by bisphosphonates - or another one, preferably treated with them? Acta Orthop 2006; 77: 693-4.
9. Hansen T, Kunkel M, Springer E, et al. Actinomycosis of the jaws - histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 2007; 451: 1009-17.
10. Naik NH, Russo TA. Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces. Clin Infect Dis 2009; 49: 1729-32.
11. Saussez S, Javadian R, Hupin C, et al. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope 2009; 119: 323-9.
12. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008; 66: 767-75.
13. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010; 48: 221-3.
14. Burr DB, Allen MR. Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthod Craniofac Res 2009; 12: 221-8.
15. Ali-Erdem M, Burak-Cankaya A, Cemil-Isler S, et al. Extraction socket healing in rats treated with bisphosphonate: Animal model for bisphosphonate related osteonecrosis of jaws in multiple myeloma patients. Med Oral Patol Oral Cir Bucal 2011; 1: 879-83.
16. Lopez-Jornet P, Camacho-Alonso F, Molina-Minano F, Gomez-Garcia F, Vicente-Ortega V. An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. J Oral Pathol Med 2010; 39: 697-702.
17. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 2009; 45: 164-72.
18. Jahn K, Stoddart MJ. Viability assessment of osteocytes using histological lactate dehydrogenase activity staining on human cancellous bone sections. Methods Mol Biol 2011; 740: 141-8.
19. Phillips CA, Hughes DR, Huja SS. Modifications of the lactate dehydrogenase assay, a histochemical determinant of osteocyte viability - a qualitative study. Acta Histochem 2009; 111: 166-71.
20. Stoddart MJ, Furlong PI, Simpson A, Davies CM, Richards RGA. Comparison of non-radioactive methods for assessing viability in ex vivo cultured cancellous bone: technical note. Eur Cell Mater 2006; 12: 16-25, Discussion 16-25.
21. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005; 34: 120-3.
22. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4.
23. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99-102.
24. Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008; 26: 4634-8.
25. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-23.
26. Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 2005; 71: 111-3.
27. Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005; 128: 738.
28. Aspenberg P, Agholme F, Magnusson P, Fahlgren A. Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening. Bone 2011; 48: 225-30.
29. Astrand J, Skripitz R, Skoglund B, Aspenberg P. A rat model for testing pharmacologic treatments of pressure-related bone loss. Clin Orthop Relat Res 2003; 409: 296-305.
30. Huja SS, Fernandez SA, Phillips C, Li Y. Zoledronic acid decreases bone formation without causing osteocyte death in mice. Arch Oral Biol 2009; 54: 851-6.
31. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011; 26: 229-38.
32. Bonewald LF. Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci 2007; 1116: 281-90.